Lantus (insulin glargine) / Sanofi - LARVOL DELTA

In brief: Kirsty - an insulin aspart interchangeable with NovoLog. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study. (PubMed, J Gen Intern Med) - "Basaglar® release was associated with spending reductions that accelerated after Semglee® availability. Biosimilar availability was associated with increases in glargine users and users per fixed-dollar amount. This study provides supportive evidence for biosimilar adoption policies."

Journal • Real-world evidence • Diabetes • Metabolic Disorders

Assessing the Value of Biosimilars: A Cost-Effectiveness Approach for Managed Care Organizations. (PubMed, J Pharm Pract) - "Biologics included Humira, Remicade, and Lantus, with biosimilars Cyltezo, Avsola, and Semglee. Pharmacists can help lead biosimilar use through counseling and substitution protocols. Greater alignment between clinical evidence and formulary practices can lower costs, improve access, and promote sustainable care."

HEOR • Journal • Crohn's disease • Diabetes • Gastroenterology • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Type 1 Diabetes Mellitus

Improved Insurance Coverage Increased Biosimilar Semglee's Market Share After The FDA's Interchangeability Designation. (PubMed, Health Aff (Millwood)) - "Semglee is a biosimilar for Lantus (insulin glargine), the most-prescribed long-acting insulin in the US. These results suggest that increased adoption was mediated mainly through improved insurance coverage, with no detectable role for increased prescribing alone and only a secondary role, at most, for pharmacist substitution. Semglee's gains in market share after interchangeability suggest that easing of federal interchangeability requirements may moderately spur biosimilar adoption."

FDA event • Journal • Reimbursement • US reimbursement

NIVOLUMAB-INDUCED DKA IN A PREVIOUS NONDIABETIC (CHEST 2025) - "Patient subsequently was discharged home with Lantus and NovoLog. With the increasing use of Checkpoint inhibitors in malignancies, practitioners should be aware of potentially serious complications including DKA and worsening glycemic control. Monitoring blood glucose and HbA1C levels before and after initiation of an immune checkpoint inhibitor should be discussed with patients prior to initiating therapy, in order to help monitor for potentially serious complications."

Hypertension • Melanoma • Metabolic Disorders • Solid Tumor • Type 2 Diabetes Mellitus

X-ray crystallography reveals insulin lisargine structure and mechanisms of glucose regulation. (PubMed, Sci Rep) - "X-ray crystallography at 2.0 Å resolution revealed structural features closely resembling human insulin, crucial for optimizing drug formulations and understanding receptor interactions.In vivo experiments demonstrated that insulin lisargine exhibits superior glucose-lowering effects compared to glargine insulin (Lantus)...These findings position insulin lisargine as a promising candidate for diabetes management, offering enhanced blood glucose control, improved production efficiency, and reliable safety. The study's findings provide a foundation for the development of more effective insulin analogs, addressing critical needs in diabetes therapy."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Derived time-in-ranges in insulin-naive older adults with type 2 diabetes treated with insulin glargine 300 U/mL vs degludec 100 U/mL: a BRIGHT trial post-hoc analysis (EASD 2025) - P4 | "In PWT2D, Gla-300 and IDeg-100 improved dTIR, reduced dTAR, without increasing dTBR in older participants (≥70 years)."

Clinical • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of time of injection on the efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes: exploratory analysis of the Soli-D study (EASD 2025) - P3 | "Clinical Trial Registration Number: NCT05413369 Background and aims: The Soli-D study demonstrated better glycaemic control and body weight (BW) benefits with iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide, vs a fixed-ratio of insulin degludec + insulin aspart (IDegAsp) at 24 weeks in Chinese adults with type 2 diabetes (T2D) suboptimally controlled with glucose-lowering oral agents (OADs)... iGlarLixi injected before breakfast demonstrated better HbA1c and average 2-h PPG control compared with IDegAsp in T2D Chinese adults suboptimally controlled with OADs, regardless of IDegAsp injection time, while also providing better overall glycaemic control and BW benefits with lower insulin doses and less hypoglycaemia risk."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycaemic outcomes when switching to iGlarLixi from premixed insulin (PI) in adults with type 2 diabetes by iGlarLixi pen subgroups: post hoc analysis of Soli-SWITCH (EASD 2025) - P4 | "In people with T2D switching from PI, glycaemic improvements were similar across iGlarLixi pen subgroups, despite differences in BL characteristics. This highlights the flexibility of iGlarLixi to adapt to insulin dose needs and optimise Lixi dosage."

Clinical • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Early glycaemic improvement when switching to iGlarLixi from premixed insulins in adults with type 2 diabetes: a post hoc analysis of Soli-SWITCH (EASD 2025) - P4 | "In adults with T2D who switched from PI to iGlarLixi, glycaemic control improved in the first weeks of transitioning (Weeks 0-3) and continued to improve to Week 12."

Clinical • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The efficacy and safety of iGlarLixi in insulin-naive adults with type 2 diabetes by baseline A1c and diabetes duration: posthoc analysis of Soli-CGM (EASD 2025) - P4 | "In adults with T2D, iGlarLixi improved the TIR without ADA Level 3 hypoglycemia, regardless of baseline HbA1c or diabetes duration."

Clinical • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus® (clinicaltrials.gov) - P1 | N=114 | Completed | Sponsor: Xentria, Inc. | Recruiting ➔ Completed

Trial completion

Clinical Application Research on the Improvement of Diabetic Neuropathic Pain by Loxenatide (ChiCTR) - P=N/A | N=60 | Recruiting | Sponsor: Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University

New trial • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Neuralgia • Pain

Euglycemic Diabetic Ketoacidosis With Recent Initiation Of A SGLT2 Inhibitor Medication In A Patient With T2D (ENDO 2025) - "The patient was previously on dulaglutide and metformin, however, she was only prescribed empagliflozin for current diabetes management...The patient was discharged with Lantus 20 units and sliding scale insulin (SSI); empagliflozin was discontinued...Additionally, this case emphasizes that EDKA can develop within a few days of initiating a SGLT2 inhibitor even among individuals without type 1 diabetes or insulin deficiency. A delay in diagnosis and treatment of EDKA can lead to worse outcomes including death."

Clinical • Late-breaking abstract • Back Pain • Cardiovascular • Diabetes • Glaucoma • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Ophthalmology • Pain • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Navigating the Uncertainty: Atypical Diabetes Mellitus with Negative Biomarkers and Complex Management (ENDO 2025) - "He was discharged with insulin (Lantus 8 units and Novolog 2 units TID) and metformin (METF) 1000 mg BID.Two weeks later when he was evaluated in clinic he was only taking METF with small doses of short-acting insulin, as needed...Patient was trialed with acarbose with no effect on BG, then a dipeptidyl peptidase-4 (DDP-4) inhibitor... This case highlights the complexity involved in diagnosing and managing atypical forms of DM, including LADA, monogenic, and ketosis-prone DM. It is a spectrum, which may present with features of both type 1 and type 2 DM but lacks definitive biomarkers. Clinicians should consider the atypical forms in adult patients with new-onset diabetes and atypical presentations, especially when there is an absence of typical autoimmune markers."

Biomarker • Diabetes • Diabetic Retinopathy • Fatigue • Hypoglycemia • Immunology • Metabolic Disorders • Renal Disease • Retinal Disorders • Type 1 Diabetes Mellitus

Unraveling The Diagnosis: A Case Of HNF1A-MODY Misclassified As Type 1 Diabetes (ENDO 2025) - "He was overweight at diagnosis, started on metformin, then transitioned to insulin due to poor glycemic control...His regimen was adjusted to include Lantus, Novolog, and Trulicity, improving HbA1c to 7.9%...He was transitioned to glipizide, pioglitazone, and Trulicity, achieving an HbA1c of 6.9%.This case emphasizes the need to reassess diabetes diagnoses in patients with poor control and strong family histories...This case emphasizes the need to reassess diabetes diagnoses in patients with poor control and strong family histories. Misclassification as T1DM led to years of ineffective insulin therapy. A comprehensive evaluation, including C-peptide, antibody testing, and genetic analysis, enabled correct diagnosis and optimized therapy."

Clinical • Late-breaking abstract • Diabetes • Endocrine Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • HNF1A

Unique Case of an 11-Year-Old Boy With Donohue Syndrome (ENDO 2025) - "He did not respond to high-dose Lantus... We report a rare presentation of Donohue Syndrome in a male patient, illustrating the early onset of severe hyperinsulinemia as well as the dysmorphic facial characteristics, hepatomegaly, and significant growth restriction. Genetic testing confirmed a pathogenic INSR mutation. Management focused on strict monitoring of glucose levels and a specialized diet."

Clinical • Dermatology • Developmental Disorders • Diabetes • Gynecology • Hepatology • IR

Continuous glucose monitoring versus fasting blood glucose basal insulin titration: a retrospective analysis. (PubMed, Diabetes Metab Syndr) - "This study established that the 1-h am nadir can potentially be used as an FBG surrogate for basal insulin titration in T2D."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Rare Presentation Of Hypoglycemia In A Patient With A History Of Diabetes And Bariatric Surgery (ENDO 2025) - "Head CT was unremarkable.Endocrinology recommended ongoing inpatient glucose monitoring, low-dose basal insulin (Lantus 5 units daily), and small, frequent meals...Hypoglycemia may be multifactorial, related to altered absorption, increased insulin sensitivity, or dosing issues. Outpatient evaluation is ongoing."

Bariatric surgery • Clinical • Late-breaking abstract • Surgery • CNS Disorders • Depression • Diabetes • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Hypoglycemia • Metabolic Disorders • Psychiatry • Solid Tumor • Type 1 Diabetes Mellitus

Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024. (PubMed, Pharmacy (Basel)) - "The introduction of biosimilars does not automatically result in altered prescribing practices, though we show that the most commonly prescribed iGlar was also the least expensive product at the end of the analysis period. At launch and for several years after, biosimilars failed to gain strong utilization, despite cost advantages, highlighting the need for active switching policies and prescriber engagement."

Journal • Diabetes • Metabolic Disorders

In brief: Merilog - a NovoLog biosimilar. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Post-marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States: A disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) database. (PubMed, Diabetes Obes Metab) - "Findings identified significant post-marketing safety signals of Lantus and Semglee. Longitudinal studies are warranted to verify these signals."

Adverse events • Journal • P4 data • Diabetes • Hypoglycemia • Lipodystrophy • Metabolic Disorders

Post-surgical biliary pancreatitis and GAD positive diabetes: a rare case of Type 3c DM with Autoimmune features (ESPE-ESE 2025) - "Pain control due to opioid intolerance (hallucinations on morphine and nausea with oxycodone) required PCA fentanyl 20 mcg bolus, paracetamol, and diclofenac supplement...The patient was managed with basal-bolus insulin (Lantus 28 units nightly, Novorapid 8-14 units per meal ) and sliding scale correction for blood glucose 10 mmol/L. The patient was discharged with a management plan of Creon 250,000 units and Humalog 12-20 units with a meal. Tresiba long-acting double strength 84 units at night... This is an atypical instance of type 3c diabetes accompanied by post-surgical pancreatitis, biliary blockage, and a rapid onset of GAD-positive diabetes. Acute pancreatitis has been known to elevate GAD-antibody levels, which can result in insulin-dependent diabetes. The presented case is rare as GAD antibody levels are typically lower in autoimmune diabetes (less than 100 U/ML)."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Diabetes • Fatigue • Gastroenterology • Hepatology • Immunology • Insomnia • Metabolic Disorders • Pain • Pancreatitis • Pulmonary Disease • Respiratory Diseases • Sleep Disorder • Type 1 Diabetes Mellitus

Afrezza® INHALE-1 Study in Pediatrics (clinicaltrials.gov) - P3 | N=319 | Completed | Sponsor: Mannkind Corporation | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Pharmacokinetics, Pharmacodynamics, and Bioequivalence of Test Insulin Glargine Versus Reference Preparation (Lantus®) in Healthy Male Volunteers-By Euglycemic Clamp Technique. (PubMed, Pharmaceutics) - "There was no clinically significant adverse reaction observed during the experiment. The glucose clamp has been established and bioequivalence between test preparation and reference preparation has been demonstrated."

Journal • PK/PD data • Diabetes • Metabolic Disorders